Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors

World Journal of Surgical Oncology

Adolfo Pisanu¹  Isabella Reccia¹  Federica Porru¹  Alessandra Saba¹  Mauro Podda¹ 

[1] Department of Surgery, University of Cagliari, Azienda Ospedaliero-Universitaria, Presidio Policlinico di Monserrato, Blocco G, SS 554 km 4, Monserrato, 500 - 09042, Cagliari, Italy

关键词: Prognosis;    Recurrence;    Lymph node metastasis;    Widely invasive carcinoma;    Minimally invasive carcinoma;    Follicular thyroid carcinoma;   

Others  :  1218723
DOI  :  10.1186/s12957-015-0612-8

 received in 2015-01-06, accepted in 2015-05-22,  发布年份 2015

【 摘 要 】

Background

Evidence on the biological behavior and clinical courses of minimally invasive and widely invasive follicular thyroid carcinoma (MI-FTC, WI-FTC) is still debatable. The current study was conducted to identify differences between MI and WI tumors and those prognostic parameters influencing late outcome such as local recurrence and survival.

Methods

From January 1998 to October 2013, 71 patients were operated on in our department because of a FTC. A retrospective cohort study was carried out to compare 42 MI-FTC and 29 WI-FTC. The comparison involved evaluation of patient characteristics, tumor characteristics, tumor staging, and risk assessment.

Results

A diameter greater than 4.0 cm, the presence of vascular invasion, the TNM stage III–IVA, and the high risk at AMES system risk stratification were independent factors significantly related to the presence of a WI-FTC. The only independent predictor of recurrence and disease-free survival at 10-year follow-up was a tumor size greater than 4.0 cm.

Conclusions

More attention must be paid in the postoperative tumor re-staging of those patients with tumor size larger than 4.0 cm, which was the only parameter predicting recurrence and influencing disease-free survival. Nevertheless, definitive recommendations cannot be made without a longer follow-up.

【 授权许可】

   
2015 Podda et al.

【 参考文献 】

• [1]Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M et al.. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospective collected, retrospectively analyzed clinical trial. Ann Surg. 2009; 249:1023-31.
• [2]Ito Y, Hirokawa M, Masuoka H, Yabuta T, Fukushima M, Kihara M et al.. Distant metastasis at diagnosis and large tumor size are significant prognostic factors of widely invasive follicular thyroid carcinoma. Endocr J. 2013; 60:829-33.
• [3]De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, et al. Actual incidence and clinical behavior of follicular thyroid carcinoma: an institutional experience. Sci World J. 2014. article ID 952095, http://dx.doi.org/10.1155/2014/952095.
• [4]DeLellis RA, Lloyd RV, Heitz PU et al.. World Health Organization classification of tumors: pathology and genetics of tumors of endocrine organs. IARC Press, Lyon; 2004.
• [5]Kim HJ, Sung JY, Oh YL, Kim JH, Son YI, Min YK, et al. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck. 2013. doi: 10.1002/hed.23511.
• [6]O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualized based on degree of capsular and vascular invasion. Eur J Surg Oncol. 2011; 37:181-5.
• [7]van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ et al.. Follicular thyroid carcinoma with capsular invasion alone: a non threatening malignancy. Surgery. 1992; 112:1130-6.
• [8]Huang CC, Hsueh C, Liu FH, Chao TZ, Lin JD. Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas. Surg Oncol. 2011; 20:1-6.
• [9]Lo CY, Chan WF, Lam KY, Wam KY. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005; 242:708-15.
• [10]Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Yuen KT et al.. Follicular thyroid carcinoma: prognostic factors and the role of radioiodine. Cancer. 2002; 95:488-98.
• [11]Ban EJ, Andrabi A, Grodski S, Yeung M, Mclean C, Serpell J. Follicular thyroid cancer: minimally invasive tumors can give rise to metastases. ANZ J Surg. 2012; 82:136-9.
• [12]Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implication for cancer staging. Ann Surg Oncol. 2007; 14:730-8.
• [13]D’Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS et al.. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004; 100:1123-9.
• [14]Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hürthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow up. Histopathology. 2004; 44:35-9.
• [15]Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th edn, pp 87–96. Springer, New York; 2010.
• [16]Pisanu A, Deplano D, Pili M, Uccheddu A. Larger tumor size predicts nodal involvement in patients with follicular thyroid carcinoma. Tumori. 2011; 97:296-303.
• [17]Pisanu A, Di Chiara B, Reccia I, Uccheddu A. Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes. World J Surg. 2010; 34:836-43.
• [18]British Thyroid Association, Royal College of Physicians. British Thyroid Association Guidelines for the management of thyroid cancer. 2. 2007. http://www.british-thyroid-association.org/Guidelines/
• [19]Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al.. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4:e297.
• [20]Cady B, Rossi R, Silverman M, Wool M. Further evidence of the validity of risk group definition in differentiated thyroid carcinoma. Surgery. 1985; 98:1171-8.
• [21]Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009; 33:460-8.
• [22]Dionigi G, Kraimps J-L, Schmid KW, Hermann M, Sheu-Grabellus S-Y, De Wailly P et al.. Minimally invasive follicular thyroid cancer (MIFTC)—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014; 399:165-84.
• [23]Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K et al.. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg. 2007; 31:1417-24.
• [24]Thompson LD, Wieneke JA, Pall E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001; 91:505-24.
• [25]Goffredo P, Cheung K, Roman SA, Sosa JA. Can minimally invasive follicular thyroid carcinoma be approached as a benign lesion? A population-level analysis of survival among 1.200 patients. Ann Surg Oncol. 2013; 20:767-72.
• [26]Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H et al.. Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid. 2012; 22:798-804.
• [27]Paphavasit A, Thompson GB, Hay ID, Grant CS, van Heerden JA, Ilstrup DM et al.. Follicular and Hürthle cell thyroid neoplasms: is frozen-section evaluation worthwhile? Arch Surg. 1997; 132:674-80.
• [28]Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized prospective evaluation of frozen section analysis for follicular neoplasms of the thyroid. Ann Surg. 2001; 233:716-22.
• [29]Bronner MP, Hamilton R, LiVolsi VA. Utility of frozen section on follicular lesions of the thyroid. Endocrinol Pathol. 1994; 5:154-61.
• [30]Rios A, Rodriguez JM, Ferri B, Martinez-Barba E, Febrero B, Parrilla P. Are prognostic scoring systems of value in patients with follicular thyroid carcinoma? Eur J Endocrinol. 2013; 169:821-7.
• [31]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al.. American Thyroid Association Guidelines Taskforce: Management guidelines for patient with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16:109-41.
• [32]Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154:787-803.
• [33]Alfalah H, Cranshaw I, Jany T, Arnalsteen L, Leteurtre E, Cardot C et al.. Risk factors for lateral cervical lymph node involvement in follicular thyroid carcinoma. World J Surg. 2008; 32:2623-6.